Nevro Corp Stock News

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors continue to be optimistic about Nevro (NVRO), owing to its strength in the global SCS market.

Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.

Nevro's (NVRO) worldwide revenues improved on a year-over-year basis in Q3, partly owing to robust domestic performance.

Nevro Corporation (NYSE:NVRO ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Julie Dewey - Chief Corporate Communications & IR Officer Keith Grossman - Chairman, CE

Nevro (NVRO) delivered earnings and revenue surprises of 12.68% and 1.40%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Nevro, Masimo, Abiomed and Glaukos are part of the Zacks top Analyst Blog.

PROCEPT BioRobotics Corporation (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

Let us take a look at some MedTech stocks, NVRO, MASI, ABMD and GKOS, which are poised to beat on third-quarter earnings.

NextGen's (NXGN) second-quarter fiscal 2023 results reflect strength in both its revenue sources.

Catalent's (CTLT) Q1 earnings are likely to have been driven by robust segmental performances.

Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Continued strength in Abiomed's (ABMD) Impella product line is expected to have driven Q2 sales.